These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 24451586)

  • 1. Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach.
    Wright MH; Clough B; Rackham MD; Rangachari K; Brannigan JA; Grainger M; Moss DK; Bottrill AR; Heal WP; Broncel M; Serwa RA; Brady D; Mann DJ; Leatherbarrow RJ; Tewari R; Wilkinson AJ; Holder AA; Tate EW
    Nat Chem; 2014 Feb; 6(2):112-21. PubMed ID: 24451586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homology modeling and molecular dynamics simulation of N-myristoyltransferase from Plasmodium falciparum: an insight into novel antimalarial drug design.
    Paul P; Chowdhury A; Das Talukdar A; Choudhury MD
    J Mol Model; 2015 Mar; 21(3):37. PubMed ID: 25663521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Selective Inhibitors of
    Harupa A; De Las Heras L; Colmenarejo G; Lyons-Abbott S; Reers A; Caballero Hernandez I; Chung CW; Charter D; Myler PJ; Fernández-Menéndez RM; Calderón F; Palomo S; Rodríguez B; Berlanga M; Herreros-Avilés E; Staker BL; Fernández Álvaro E; Kaushansky A
    J Med Chem; 2020 Jan; 63(2):591-600. PubMed ID: 31850752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors.
    Schlott AC; Mayclin S; Reers AR; Coburn-Flynn O; Bell AS; Green J; Knuepfer E; Charter D; Bonnert R; Campo B; Burrows J; Lyons-Abbott S; Staker BL; Chung CW; Myler PJ; Fidock DA; Tate EW; Holder AA
    Cell Chem Biol; 2019 Jul; 26(7):991-1000.e7. PubMed ID: 31080074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ternary structure of Plasmodium vivaxN-myristoyltransferase with myristoyl-CoA and inhibitor IMP-0001173.
    Bolling C; Mendez A; Taylor S; Makumire S; Reers A; Zigweid R; Subramanian S; Dranow DM; Staker B; Edwards TE; Tate EW; Bell AS; Myler PJ; Asojo OA; Chakafana G
    Acta Crystallogr F Struct Biol Commun; 2024 Oct; 80(Pt 10):269-277. PubMed ID: 39291304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Myristoylation as a Drug Target in Malaria: Exploring the Role of N-Myristoyltransferase Substrates in the Inhibitor Mode of Action.
    Schlott AC; Holder AA; Tate EW
    ACS Infect Dis; 2018 Apr; 4(4):449-457. PubMed ID: 29363940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel and ligand-efficient inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferase.
    Rackham MD; Brannigan JA; Moss DK; Yu Z; Wilkinson AJ; Holder AA; Tate EW; Leatherbarrow RJ
    J Med Chem; 2013 Jan; 56(1):371-5. PubMed ID: 23170970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of inhibitors of Plasmodium falciparum N-myristoyltransferase, a promising target for antimalarial drug discovery.
    Yu Z; Brannigan JA; Moss DK; Brzozowski AM; Wilkinson AJ; Holder AA; Tate EW; Leatherbarrow RJ
    J Med Chem; 2012 Oct; 55(20):8879-90. PubMed ID: 23035716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring Subsite Selectivity within
    Rodríguez-Hernández D; Fenwick MK; Zigweid R; Sankaran B; Myler PJ; Sunnerhagen P; Kaushansky A; Staker BL; Grøtli M
    J Med Chem; 2024 May; 67(9):7312-7329. PubMed ID: 38680035
    [No Abstract]   [Full Text] [Related]  

  • 10. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
    Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
    Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization and in vitro evaluation of novel enantiomerically-pure sulphonamide antimalarials.
    Anusha S; Sinha A; Babu Rajeev CP; Chu TT; Mathai J; Ximei H; Fuchs JE; Shivananju N; Bender A; Preiser PR; Rangappa KS; Basappa ; Chandramohanadas R
    Org Biomol Chem; 2015 Nov; 13(43):10681-90. PubMed ID: 26347024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP).
    Rackham MD; Brannigan JA; Rangachari K; Meister S; Wilkinson AJ; Holder AA; Leatherbarrow RJ; Tate EW
    J Med Chem; 2014 Mar; 57(6):2773-88. PubMed ID: 24641010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
    Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
    Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum.
    Bowyer PW; Gunaratne RS; Grainger M; Withers-Martinez C; Wickramsinghe SR; Tate EW; Leatherbarrow RJ; Brown KA; Holder AA; Smith DF
    Biochem J; 2007 Dec; 408(2):173-80. PubMed ID: 17714074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QSAR Study of
    Santos-Garcia L; de Mecenas Filho MA; Musilek K; Kuca K; Ramalho TC; da Cunha EFF
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30217086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria.
    Wadood A; Ghufran M; Hassan SF; Khan H; Azam SS; Rashid U
    Pharm Biol; 2017 Dec; 55(1):19-32. PubMed ID: 27650666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases.
    Hocková D; Keough DT; Janeba Z; Wang TH; de Jersey J; Guddat LW
    J Med Chem; 2012 Jul; 55(13):6209-23. PubMed ID: 22725979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
    González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
    Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis.
    Tate EW; Bell AS; Rackham MD; Wright MH
    Parasitology; 2014 Jan; 141(1):37-49. PubMed ID: 23611109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of new oxospiro chromane quinoline-carboxylate antimalarials that arrest parasite growth at ring stage.
    Jameel E; Madhav H; Agrawal P; Raza MK; Ahmedi S; Rahman A; Shahid N; Shaheen K; Gajra CH; Khan A; Malik MZ; Imam MA; Kalamuddin M; Kumar J; Gupta D; Nayeem SM; Manzoor N; Mohammad A; Malhotra P; Hoda N
    J Biomol Struct Dyn; 2023; 41(24):15485-15506. PubMed ID: 36970842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.